Archived explainer. For the current picture see today's HROW page.
HARROW INC (HROW) is drawing unusual attention today. Our newswire has captured 2 stories on HROW across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
HROW stock is moving modestly lower in early trading after the release of interim data from clinical studies presented at the ASRS 2026 Annual Meeting. The stock opened at $46.70 and has since traded as low as $45.66, with a last price of $46.00. The data showed mixed results for Harrow’s biosimilar and therapeutic products, with some positive outcomes but no definitive breakthroughs that would immediately boost investor confidence. The session has seen 0.2 million shares traded so far, below the 3-month average.
Harrow and Samsung Bioepis presented interim data from a post-marketing surveillance study on SB11, a biosimilar to Lucentis. The study showed treatment-naïve patients experienced mean best-corrected visual acuity (BCVA) and central subfield thickness (CST) improvements of -0.10 and -95 µm, respectively, over a 24-week follow-up period. Harrow also highlighted an interim study of 150 patients comparing IHEEZO with subconjunctival lidocaine, along with the ongoing QUELL trial, which is enrolling about 236 subjects and expects topline data in Q4 2026. While these developments reflect ongoing clinical validation, the market appears to be reacting cautiously to the incremental nature of the updates.
The stock is trading within its 52-week range of $28.54 to $54.85, with a market cap of $1.7 billion. The company remains unprofitable, with a trailing twelve-month (TTM) earnings per share (EPS) of -0.40 and a net margin of -5.6%. Revenue has grown by 26.2% TTM, indicating some operational momentum. Recent insider transactions have been positive, with four buys totaling $469,000 reported in the last 90 days, including purchases by the CEO and two directors. The stock’s beta of 0.25 suggests it is less volatile than the broader market.
Investors should monitor the topline data from the QUELL trial expected in Q4 2026, as well as any further updates from ongoing clinical studies. The breadth of coverage and analyst reactions to these developments will also be key indicators of market sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Treatment-naïve patients showed mean BCVA and CST improvements of -0.10 and -95 µm, while follow-up lasted up to 24 weeks after dosing.
An interim study of 150 patients compared IHEEZO with subconjunctival lidocaine; QUELL is enrolling about 236 subjects, with topline data expected Q4 2026.
More on HROW: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier HROW move explainers: 2026-07-27 · 2026-07-21 · 2026-07-20